Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001636282-24-000107
Filing Date
2024-11-18
Accepted
2024-11-18 16:03:42
Documents
108
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 10-K syre-20231231.htm   iXBRL 10-K/A 1519228
2 EX-23.1 ex231spyre2023formconsent1.htm EX-23.1 2365
3 EX-31.1 spyre-20241231xex311a.htm EX-31.1 9604
4 EX-31.2 spyre-20241231xex312a.htm EX-31.2 9613
5 EX-32.1 spyre-20241231xex321a.htm EX-32.1 6309
  Complete submission text file 0001636282-24-000107.txt   10779209

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT syre-20231231.xsd EX-101.SCH 86887
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT syre-20231231_cal.xml EX-101.CAL 95106
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT syre-20231231_def.xml EX-101.DEF 577132
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT syre-20231231_lab.xml EX-101.LAB 928738
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT syre-20231231_pre.xml EX-101.PRE 752056
111 EXTRACTED XBRL INSTANCE DOCUMENT syre-20231231_htm.xml XML 1603158
Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Spyre Therapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-37722 | Film No.: 241471431
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)